Lu Wang
Impact in
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
- Oncology top 0.5%
- Lung Cancer Research Studies
Papers in
-
- RNA modifications and cancer 20
-
- Lung Cancer Treatments and Mutations 34
- Sarcoma Diagnosis and Treatment 33
- Co-authors
- Marc Ladanyi (36 shared papers)Mark G. Kris (17 shared papers)Alexander Drilon (13 shared papers)Stephen C. Winans (4 shared papers)Maureen F. Zakowski (7 shared papers)Meera Hameed (18 shared papers)Eckhard Ficker (1 shared paper)Arthur Brown (1 shared paper)
- Journals
- Journal of Clinical Oncology (11 papers)Modern Pathology (9 papers)Cancer Research (8 papers)Clinical Cancer Research (8 papers)Oncotarget (8 papers)
- Partner nations
- ChinaUnited StatesCanada
In The Last Decade
Lu Wang
520 papers receiving 13.9k citations
Lu Wang's Hit Papers
Peers
Comparison fields: 5 of 193
- Cancer Research 1.9k
- Oncology 3.2k
- Pulmonary and Respiratory Medicine 3.6k
- Molecular Biology 5.6k
- Rheumatology 1.1k
Countries citing papers authored by Lu Wang
This map shows the geographic impact of Lu Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Wang more than expected).
Fields of papers citing papers by Lu Wang
This network shows the impact of papers produced by Lu Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Wang. The network helps show where Lu Wang may publish in the future.
Co-authors
The 25 scholars most cited alongside Lu Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 552 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | High-throughput genotyping by whole-genome resequencing Hit paper breakdown → | 2009 | 646 |
| 2 | The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma Hit paper breakdown → | 2011 | 512 |
| 3 | 2013 | 342 | |
| 4 | Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial Hit paper breakdown → | 2016 | 327 |
| 5 | 2013 | 312 | |
| 6 | 2003 | 277 | |
| 7 | 2013 | 216 | |
| 8 | 2011 | 214 | |
| 9 | 2013 | 207 | |
| 10 | 2015 | 202 | |
| 11 | 2014 | 165 | |
| 12 | 2014 | 163 | |
| 13 | 2010 | 158 | |
| 14 | 2016 | 135 | |
| 15 | 2012 | 132 | |
| 16 | 2015 | 128 | |
| 17 | 2009 | 124 | |
| 18 | 2007 | 122 | |
| 19 | 2018 | 116 | |
| 20 | 2012 | 114 |
About Lu Wang
Lu Wang is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine, Oncology, Surgery and Epidemiology, having authored 552 papers that have together received 14.1k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (34 papers), Sarcoma Diagnosis and Treatment (33 papers), Cancer Genomics and Diagnostics (33 papers), Acute Myeloid Leukemia Research (20 papers), RNA modifications and cancer (20 papers), HIV, Drug Use, Sexual Risk (18 papers), Colorectal Cancer Treatments and Studies (18 papers) and HIV/AIDS Research and Interventions (17 papers). The work is most often cited by research in Cancer Research (1.9k citations), Oncology (3.2k citations), Pulmonary and Respiratory Medicine (3.6k citations), Molecular Biology (5.6k citations) and Rheumatology (1.1k citations). Lu Wang has collaborated with scholars based in China, United States and Canada. Frequent co-authors include Marc Ladanyi, Mark G. Kris, Alexander Drilon, Stephen C. Winans, Maureen F. Zakowski, Meera Hameed, Eckhard Ficker, Arthur Brown, Adrienne T. Dennis and Maria E. Arcila. Their work appears in journals such as Journal of Clinical Oncology, Modern Pathology, Cancer Research, Clinical Cancer Research and Oncotarget.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.